Last reviewed · How we verify
Ropivocaine
Ropivocaine is a Small molecule drug developed by Cui Xulei. It is currently in Phase 1 development.
Ropivacaine is used in various medical procedures, including hemorrhoidectomy, pain management, and paravertebral block, as a solution with or without epinephrine. It is administered via perineal block for intraoperative use in procedures such as hemorrhoidectomy.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ropivocaine |
|---|---|
| Sponsor | Cui Xulei |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- High Versus Low Adductor Canal Block (PHASE4)
- IntraopeRativE Use of periNeal Block for Hemorrhoidectomy (NA)
- CTPVB for Hepatectomy (NA)
- Ultrasound-guided Continuous Adductor Canal Block for Analgesia After Total Knee Replacement: Comparison of Short-axis and Long-axis Techniques (NA)
- Modified Paramedic Sagittal vs. Transverse TMQLB (NA)
- Novel Technique of Analgesia Following Open Liver Resection (PHASE4)
- Local Anaesthetic Following Hernia Repair (PHASE1)
- Epidural Analgesia on Electrophysiological Function (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivocaine CI brief — competitive landscape report
- Ropivocaine updates RSS · CI watch RSS
- Cui Xulei portfolio CI
Frequently asked questions about Ropivocaine
What is Ropivocaine?
Who makes Ropivocaine?
What development phase is Ropivocaine in?
Related
- Manufacturer: Cui Xulei — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing